ClinicalTrials.Veeva

Menu

Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients

UCB logo

UCB

Status

Completed

Conditions

Epilepsy

Study type

Observational

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment. Adverse effects and considerations to modify the therapy will be assessed in pediatric and adult patients with controlled as well as uncontrolled epilepsy with different seizure types

Enrollment

1,000 estimated patients

Sex

All

Ages

4+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Male and female patients from the age of 4 years
  • Confirmed diagnosis of epilepsy requiring AED treatment
  • Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
  • Treatment must be stable for at least 3 months prior to assessment
  • Absence of other severe and/or uncontrolled symptomatic chronic illness

Trial contacts and locations

54

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems